

## FUND OBJECTIVE

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

For informational purposes only. This document should be used to highlight some of the criteria to be used by index provider when publishing index constituents and is not comprehensive.\*

ETF Category:  
Growth - People & Demographics

As of 4/1/25

Index Provider: SOLACTIVE



## KEY FEATURES



High Growth  
Potential



Structural  
Tailwinds



Targeted  
Exposure

## SOLACTIVE GENOMICS INDEX

## SELECTION

- The index is designed to track the performance of companies that have or are expected to have significant exposure to the field of Genomics by using a natural language processing (NLP) algorithm that evaluates publicly available information.
- Companies are ranked by their Index Score based on the reference frequency of the theme specific keywords and classified based on revenue exposure from relevant activities:
  - Pure-Play: Derives at least 50% of revenues from Genomics Activities.
  - Pre-Revenue: Has primary business operations in Genomics Activities but does not currently generate revenues.
  - Diversified: Derives revenues from Genomics Activities but less than 50%
- Genomics Activities include but are not limited to: Gene editing, Genomic sequencing, Development and testing of genetic medicine/therapies, and Computational genomics and genetic diagnostics
- The remaining companies are then ranked by their Index Score
  - The 20 highest ranked Pure-Play/Pre-Revenue Companies and the 5 highest ranked Diversified companies are selected.
  - Current constituents are retained by weight priority as of the selection day, up to a maximum of 50 index components, provided they maintain an Index Score and meet eligibility criteria.
- If the total number of index constituents is still below 50, companies that satisfy eligibility requirements are added according to their Index Score. Diversified Index constituents will be capped at 10 index constituents.

## SELECTION POOL

- Primary listing is in one of the Developed Countries, as defined by the Solactive Country Classification, or ADRs that have primary listing in Emerging Countries.
- Market capitalization of at least \$200M for new index constituents and \$160M for existing constituents
- Free float percentage of total shares outstanding of at least 10% of shares outstanding or a minimum free float market capitalization of \$1 billion
- Average daily trading volume in the last six months of at least \$2M for new index constituents and \$1.4M for existing constituents
- Classified under the Economy "Healthcare" in the FactSet Industries and Economic Sectors Classification.

## WEIGHTING SCHEME

- Index components are weighted according to Free Float Market Capitalization with the following constraints:
  - Each component is subject to maximum weight of 4%
  - Companies classified as Diversified are subject to a maximum weight of 2%, with the total weight of all Diversified companies capped at 10% of the index.



## REBALANCES/REVIEWS

---

- The index follows a semi-annual reconstitution schedule. Adjustments are made on the second Friday in May and November.
- An existing index constituent is only excluded if it does not have a positive Index Score or it generates less than 50% of its revenues from Genomics activities and/or is no longer classified as “Biotechnology”.
- A new company is added only if it passes all selection criteria and ranks in the top 10 in the Index Score ranking.

*For more information on the Index, please visit Solactive's website.*

---

\*For the complete and current index methodology please refer to the index provider's website. This summary document is accurate as of the time of its publication and Global X does not guarantee that it is current at any point thereafter.

The selection of the index constituents and their weighting is made by the index provider at its sole discretion.

***Carefully consider the fund's investment objectives, risks, and charges and expenses. This and other information can be found in the fund's full or summary prospectus, which may be obtained by visiting [globalxetfs.com](http://globalxetfs.com). Please read the prospectus carefully before investing.***

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO) 1 Freedom Valley Drive, Oaks, PA, 19456, which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive, nor does Solactive make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive.